Nephrogenic Systemic Fibrosis History
At Saiontz & Kirk, P.A., our lawyers are reviewing potential lawsuits for individuals who have been diagnosed with Nephrogenic Systemic Fibrosis, which has been directly linked to gadolinium-based contrast dyes used during MRI and MRA scans. Many people have contacted our office expressing concerns about the MRI contrast problems and asking questions about the history of Nephrogenic Systemic Fibrosis, which has only developed over the past ten years.
>>INFORMATION: Gadolinium MRI Contrast Problems
Nephrogenic Systemic Fibrosis (NSF), was originally referred to as Nephrogenic Fibrosing Dermopathy (NFD). It is a rare, but serious acquired disease, which has been observed in those with kidney insufficiency after receiving an MRA or MRI with contrast. It is associated with fibrosis (or scarring) of the skin and other internal organs. The symptoms usually involve thickening and hardening of the skin, which results in stiff joints and limited mobility. It is painful, debilitating and could ultimately be fatal.
>>INFORMATION: Nephrogenic Systemic Fibrosis Symptoms
HISTORICAL DEVELOPMENTS OF NSF/NFD
1988 – The first MRI contrast dye containing gadolinium was approved by the FDA. Today there are five different gadolinium dye agents on the market, which assist doctors in differentiating blood vessels from nearby tissue during an MRI scan or MRA.
1997 – The first known case was identified of a kidney patient suffering severe fibrosis of the skin, which caused restrictions on movement.
2000 – The first written documentation appeared in medical literature regarding NFD/NSF. It was presented by Shawn E. Cowper, M.D., who now heads up *Nephrogenic Systemic Fibrosis research at Yale University, where an international registry is maintained,
May 2006 – The Danish Medicines Agency posted a healthcare advisory after a connection was made between gadolinium MRI contrasts and NSF cases which occurred over a four year period at two European hospitals.
June 8, 2006 – The U.S Food and Drug Administration (FDA) published a public health advisory warning about the development of NSF/NFD after the administration of a gadolinium contrast agent during a magnetic resonance imaging scan or magnetic resonance angiography.
December 22, 2006 – The FDA indicated that they had received reports of at least 90 individuals with moderate to end-stage kidney disease who developed Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy after receiving an MRI or MRA with contrast.
January 2007 – Reports indicate that there have been approximately 400 confirmed cases of NSF worldwide. However, the true number of individuals suffering from the debilitating condition is likely much higher, as many dermatologists are unfamiliar with the diagnosis.
May 23, 2007 – The FDA requested that a black-box label be placed on all five Gadolinium contrast agents, warning of the dangers for those with kidney insufficiencies.
NEPHROGENIC SYSTEMIC FIBROSIS LAWYERS
The MRI contrast lawyers at Saiontz and Kirk, P.A. provide free consultations and claim evaluations for those who have developed problems which may be related to the MRI contrast dye. The manufacturers of these contrasts failed to properly research their product or warn about the danger of Nephrogenic Systemic Fibrosis.
No Comments • Add Your Comments